-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Benzinga·06/12/2025 16:59:43
Listen to the news
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Neutral and maintains $115 price target.